Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report
Department of Psychiatry
Adult; Antimanic Agents; Bipolar Disorder; Chronobiology Phenomena; Cyclohexanols; *Drug Resistance; Female; Follicular Phase; Humans; Menstruation; Thyroxine; Triazines; Valproic Acid
Mental and Social Health | Psychiatry | Psychiatry and Psychology
AIMS/OBJECTIVES: To evaluate lamotrigine in a woman with a 30-year history of treatment-resistant menstrually-entrained rapid cycling bipolar II disorder with follicular phase depressive and luteal phase mood elevation symptoms.
METHODS: Lamotrigine was started at 5 mg/day and gradually increased up to 300 mg/day, while venlafaxine was tapered gradually and discontinued, and divalproex sodium 500 mg/day and levothyroxine 175 mcgm/day were continued. Daily self-reported mood ratings were obtained from the patient, using ChronoRecord software.
RESULTS: As lamotrigine was increased gradually, mood cycle amplitude attenuated. There was notable decrease in the severity and duration of depressive symptoms specifically during the follicular phase of the menstrual cycle. At the time of submission of this paper, the subject had remained euthymic for a total of 12 months.
CONCLUSION: This case suggests the potential utility of lamotrigine in treatment-resistant menstrually-related rapid cycling bipolar disorder, and raises the possibility that lamotrigine might be able to treat pathological entrainment of mood with the menstrual cycle. Both of these issues merit systematic assessment.
DOI of Published Version
Bipolar Disord. 2004 Oct;6(5):435-9. Link to article on publisher's site
Becker OV, Rasgon NL, Marsh WK, Glenn T, Ketter TA. (2004). Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. Psychiatry Publications and Presentations. https://doi.org/10.1111/j.1399-5618.2004.00146.x. Retrieved from https://escholarship.umassmed.edu/psych_pp/580